ArticleBiomaterials2026
Thrombogenic characterization of alloyed and surface-modified magnesium bioresorbable metals for cardiovascular device applications.
Article in Biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Magnesium alloys show great promise for use in bioresorbable metal vascular stents due to their mechanical properties. However, considerable material engineering efforts are required to reduce the corrosion rate of magnesium and translate these stents into clinical use. Alloying elements and surface modifications are frequently used to reduce corrosion rate and retain mechanical strength for a longer time. This work sought to characterize the effects that these alloying approaches and surface modifications have on the acute thrombogenicity of magnesium scaffolds. Common magnesium alloys were assessed in conjunction with a biostable clinical control in both ex vivo whole blood and in vitro assays. Our results indicated that magnesium alloying did not affect the thrombogenicity of the material with equivalent platelet deposition and fibrin accumulation on all of the alloyed magnesium metals, as well as in the alloys' proclivity to produce fibrin or activate factor XII (FXII). In contrast, surface modifications of magnesium, specifically fluorination and anodization, increased platelet deposition and fibrin accumulation onto the magnesium surface compared to the unmodified metal. No differences were found in fibrin or FXIIa generation between surface-modified and the unmodified magnesium material. In conclusion, this research demonstrated that alloying is a viable strategy to increase magnesium corrosion resistance without affecting its thrombogenicity, whereas surface modifications to magnesium may increase the material thrombogenicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.